Harvard Bioscience (NASDAQ:HBIO) Stock Rating Lowered by Wall Street Zen

Harvard Bioscience (NASDAQ:HBIO) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Benchmark dropped their price target on Harvard Bioscience from $4.50 to $3.00 and set a “speculative buy” rating for the company in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Harvard Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.00.

Harvard Bioscience Price Performance

NASDAQ HBIO opened at $0.50 on Friday. Harvard Bioscience has a 1-year low of $0.28 and a 1-year high of $3.14. The company has a market capitalization of $22.04 million, a P/E ratio of -0.38 and a beta of 1.54. The business has a 50 day moving average price of $0.48 and a 200 day moving average price of $0.53.

Institutional Investors Weigh In On Harvard Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC grew its position in shares of Harvard Bioscience by 491.9% in the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares during the period. Marshall Wace LLP purchased a new stake in shares of Harvard Bioscience in the second quarter valued at $61,000. AMH Equity Ltd grew its position in shares of Harvard Bioscience by 3.6% in the second quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock valued at $1,557,000 after purchasing an additional 121,348 shares during the period. Pasadena Private Wealth LLC grew its position in shares of Harvard Bioscience by 23.2% in the second quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 45,872 shares during the period. Finally, Williams & Novak LLC grew its position in shares of Harvard Bioscience by 37.0% in the second quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 28,800 shares during the period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.